The decision by the U.S. Health Resources & Services Administration (HRSA) to refer six drug manufacturers to the U.S. Health and Human Services Department of the Office of The Inspector General (HHS OIG) for refusing to offer 340B discounts to covered entities that use contract pharmacies drew praise from 340B provider groups and was roundly criticized by the drug companies and their primary lobbying group.
Parties at Center of Contract Pharmacy Standoff React to HHS OIG Referral
